News Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 04/12/2025 pm IST			5-day change	1st Jan Change
2,062.00 ^DKK	+1.93%		+1.53%	+38.16%

05/12	Genmab A/S Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09:45 AM
04/12	Genmab Closes $2.5 Billion Senior Notes Offering	MT

Genmab A/S Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09:45 AM	04/12
Genmab Closes $2.5 Billion Senior Notes Offering	04/12	MT
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	04/12	GL
Genmab A/S and Genmab Finance LLC Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	04/12	CI
European Equities Close Mixed in Tuesday Trading; Euro Area Inflation Rises 2.2% in November	02/12	MT
Genmab, Pfizer's Cervical Cancer Drug Gets UK Regulatory Nod	02/12	MT
Genmab's Cervical Cancer Drug Gets UK Regulatory Approval	02/12	MT
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	02/12	GL
Genmab A/S : Articles of association dated November 20, 2025 – English	26/11	PU
Genmab A/S : has published its Articles of Association	26/11	PU
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami	24/11	GL
Genmab A/S Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 12:00 PM	22/11
Grant of Restricted Stock Units and Warrants to Employees in Genmab	21/11	GL
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	19/11	GL
Genmab A/S : Articles of association dated November 18, 2025 – English	19/11	PU
Genmab A/S : has published its Articles of Association	19/11	PU
Genmab Announces EPKINLY in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	19/11	AQ
FDA Approves Genmab's Combination Therapy for Follicular Lymphoma	19/11	FW
Genmab Unit Prices $2.5 Billion Senior Notes Offering	19/11	MT
Genmab announces pricing of private offering of senior secured notes and senior unsecured notes	19/11	RE
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility	19/11	GL
Capital Increase in Genmab as a Result of Employee Warrant Exercise	19/11	GL
Genmab Reports FDA Approval for Epkinly in Follicular Lymphoma	19/11	MT
Genmab Secures US Approval for Follicular Lymphoma Combo Therapy	19/11	MT
Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	18/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Genmab delivers strong Q3 results as pipeline advances and lower valuation attracts investors

November 07, 2025 at 08:31 pm IST

Genmab: From now on, courage to the most patient

April 01, 2025 at 08:27 pm IST